A peptide derived from alpha-fetoproteln inhibits the proliferation induced by estradiol in mammary tumor cells in culture

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 229-235

  Sierralta, Walter D ^a   Epuñan, María J ^a   Reyes, José M ^b   Valladares, Luis E ^a   Andersen, Thomas T ^c   Bennett, James A ^c   Jacobson, Herbert I ^c   Pino, Ana M ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b CLÍNICA LAS CONDES   (Chile)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Active cyclic nonapeptide; Alpha fetoprotein; Antiproliferative peptide; Estradiol dependent proliferation; Inhibition of cell growth; Mammary tumor cells; p21Cip1

Indexed keywords

ALPHA FETOPROTEIN; AROMATASE; AROMATASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTRADIOL; TAMOXIFEN; UVOMORULIN; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; BINDING SITE; BIOCHEMISTRY; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CULTURE MEDIUM; CYTOLOGY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MAMMARY GLAND; MOUSE; NUDE MOUSE; TUMOR CELL LINE;

ALPHA-FETOPROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTRADIOL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MAMMARY GLANDS, HUMAN; MICE; MICE, NUDE; PEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38749097402     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sommer S and Fuqua SA: Oestrogen receptor and breast cancer. Semin Cancer Biol 11: 339-352, 2001.
2. Tsai M and O'Malley BW: Molecular mechanism of action of steroid/thyroid superfamily members. Annual Rev Biochem 63: 451-486, 1994.
3. Batistuzzo de Madeiros SR, Krey G, Hihi AK and Wahli W: Functional interaction between the estrogen receptor and the transcription factor Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 promoter. J Biol Chem 272: 18250-18260, 1997.
4. Galienand WJ and Garcia T: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 25: 2424-2429, 1997.
5. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson JA, Kushner PJ and Scalan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510, 1997.
6. Porter W, Saville B, Hoivik D and Safe S: Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11: 1569-1580, 1999.
7. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R and Dickson RB: Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987.
8. Bates SE, Davidson NE, Valverius EM, et al: Expression of transforming growth factor-alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its posssible functional significance. Mol Endocrinol 2: 543-555, 1998.
9. Osborne KC, Schiff R, Fuqua SA and Shou J: Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7: S4338-S4342, 2001.
10. Huynh H, Yang X and Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cell. J Biol Chem 271: 1016-1021, 1996.
11. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein-kinase. Science 270: 1491-1494, 1995.
12. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK: Interaction of estrogen receptor with the regulatory subunit of phophatidylinositol-3-OH kinase. Nature 407: 538-541, 2000.
13. Santen RJ, Song RX, MacPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002.
14. Santen RJ: To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab 87: 3007-3012, 2002.
15. Gradishar WJ and Jordan VC: Clinical potential of new antiestrogens. J Clin Oncol 15: 840-852, 1997.
16. Deutsch HF: Chemistry and biology of alpha-fetoprotein. Adv Cancer Res 56: 253-312, 1991.
17. Bakker J, De Mees C, Douhard Q, Balthazart J, Gabant P, Szpirer J and Szpirer C: Alpha-fetoprotein protects the developing female mouse brain from masculinization and defeminization by estrogens. Nature Neurosci 9: 220-226, 2006.
18. Jacobson HI, Thompson WD and Janerich DT: Multiple births and maternal risk of breast cancer. Amer J Epidemiol 129: 865-873, 1989.
19. Jacobson HI, Bennet JA and Mizejewski GJ: Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res 50: 415-420, 1990.
20. Mesfin FB, Bennett JA, Jacobson HI, Zhu SJ and Andersen TT: Alpha-fetoprotein-derived antiestrotrophic octapeptide. Biochim Biophys Acta 1501: 33-43, 2000.
21. DeFreest LA, Mesfin FB, Joseph L, et al: Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization. J Pept Res 63: 409-419, 2004.
22. Bennett JA, Mesfin FB, Andersen TT, Gierthy JF and Jacobson HI: A peptide derived from α-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci USA 99: 2211-2215, 2002.
23. Bennett JA, Zhu S, Pagano-Mirarchi A, Kellom TA and Jacobson HI: Alpha-fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Clin Cancer Res 4: 2877-2884, 1998.
24. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
25. Coqueret O: New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65-70, 2003.
26. Dotto GP: p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471: M43-M56, 2000.
27. Braunsberg H, Coldham NG and Leake RE: Effects of serum type on steroid receptor binding sites and response to progestin of cultured human breast cancer cells. Eur J Cancer Clin Oncol 23: 573-576, 1987.
28. Williams D and Gorski J: Equilibrium binding of estradiol by uterine cell suspensions and whole uteri in vitro. Biochemistry 13: 5537-5542, 1974.
29. Hiscox S, Jiang WG, Obermeier K, et al: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118: 290-301, 2006.
30. Chen S: Aromatase and breast cancer. Front Biosci 3: D922-D933, 1998.
31. Parikh RR, Gildener-Leapman N, Narendran A, et al: Prevention of n-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP. Clin Cancer Res 11: 8512-8520, 2005.
32. Barnouin K, Dubuisson MI, Child ES, et al: H202 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem 277: 13761-13770, 2002.
33. Osborne CK, Boldt DH and Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433-1439, 1984.
34. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkinz HA, Bagnard D and Roche J: Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7:180-189, 2005.
35. Nicolas FJ and Hill CS: Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 22: 3698-3711, 2003.
36. Planas-Silva MD and Weinberg RA: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17: 4059-4069, 1997.
37. Prives C and Hall PA: The p53 pathway. J Pathol 187: 112-126, 1999.
38. CIP1 gene expression and the antiproliferative activity of histone acetylase inhibitors in human breast cancer cells. J Endocrinol 179: 41-53, 2003.
39. Lai A, Sarcevic B, Prall OWJ and Sutherland RL: Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21WAF1/Cip1. J Biol Chem 276: 25823-25833, 2001.